Annual Cash & Cash Equivalents
$14.13 M
-$8.01 M-36.19%
31 December 2023
Summary:
Cytosorbents annual cash & cash equivalents is currently $14.13 million, with the most recent change of -$8.01 million (-36.19%) on 31 December 2023. During the last 3 years, it has fallen by -$57.29 million (-80.21%). CTSO annual cash & cash equivalents is now -80.21% below its all-time high of $71.42 million, reached on 31 December 2020.CTSO Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$5.69 M
-$2.77 M-32.79%
30 September 2024
Summary:
Cytosorbents quarterly cash and cash equivalents is currently $5.69 million, with the most recent change of -$2.77 million (-32.79%) on 30 September 2024. Over the past year, it has dropped by -$2.67 million (-31.99%). CTSO quarterly cash and cash equivalents is now -93.54% below its all-time high of $87.98 million, reached on 30 September 2020.CTSO Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CTSO Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -36.2% | -32.0% |
| 3 y3 years | -80.2% | -90.7% |
| 5 y5 years | -36.8% | -64.4% |
CTSO Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -80.2% | at low | -90.7% | at low |
| 5 y | 5 years | -80.2% | +15.5% | -93.5% | at low |
| alltime | all time | -80.2% | +6578.2% | -93.5% | >+9999.0% |
Cytosorbents Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $5.69 M(-32.8%) |
| June 2024 | - | $8.46 M(-1.7%) |
| Mar 2024 | - | $8.61 M(-39.1%) |
| Dec 2023 | $14.13 M(-36.2%) | $14.13 M(+69.1%) |
| Sept 2023 | - | $8.36 M(-36.4%) |
| June 2023 | - | $13.15 M(-31.0%) |
| Mar 2023 | - | $19.05 M(-14.0%) |
| Dec 2022 | $22.14 M(-57.5%) | $22.14 M(-1.8%) |
| Sept 2022 | - | $22.55 M(-25.2%) |
| June 2022 | - | $30.16 M(-29.9%) |
| Mar 2022 | - | $43.02 M(-17.5%) |
| Dec 2021 | $52.14 M(-27.0%) | $52.14 M(-14.6%) |
| Sept 2021 | - | $61.04 M(-7.0%) |
| June 2021 | - | $65.61 M(-4.2%) |
| Mar 2021 | - | $68.47 M(-4.1%) |
| Dec 2020 | $71.42 M(+483.9%) | $71.42 M(-18.8%) |
| Sept 2020 | - | $87.98 M(+150.6%) |
| June 2020 | - | $35.11 M(+33.1%) |
| Mar 2020 | - | $26.39 M(+115.7%) |
| Dec 2019 | $12.23 M(-45.3%) | $12.23 M(-23.4%) |
| Sept 2019 | - | $15.98 M(-2.2%) |
| June 2019 | - | $16.34 M(-16.8%) |
| Mar 2019 | - | $19.65 M(-12.2%) |
| Dec 2018 | $22.37 M(+29.1%) | $22.37 M(-10.2%) |
| Sept 2018 | - | $24.91 M(-1.5%) |
| June 2018 | - | $25.28 M(+19.9%) |
| Mar 2018 | - | $21.09 M(+21.8%) |
| Dec 2017 | $17.32 M(+230.2%) | $17.32 M(+12.5%) |
| Sept 2017 | - | $15.40 M(-6.1%) |
| June 2017 | - | $16.40 M(+406.2%) |
| Mar 2017 | - | $3.24 M(-38.2%) |
| Dec 2016 | $5.25 M(-1.3%) | $5.25 M(-17.7%) |
| Sept 2016 | - | $6.38 M(-26.5%) |
| June 2016 | - | $8.67 M(+145.1%) |
| Mar 2016 | - | $3.54 M(-33.5%) |
| Dec 2015 | $5.32 M | $5.32 M(-28.0%) |
| Sept 2015 | - | $7.39 M(-7.9%) |
| June 2015 | - | $8.02 M(-23.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | $10.42 M(+189.0%) |
| Dec 2014 | $3.61 M(+65.2%) | $3.61 M(+731.9%) |
| Sept 2014 | - | $433.40 K(-91.1%) |
| June 2014 | - | $4.88 M(-24.0%) |
| Mar 2014 | - | $6.42 M(+193.9%) |
| Dec 2013 | $2.18 M(+26.2%) | $2.18 M(-7.1%) |
| Sept 2013 | - | $2.35 M(+25.6%) |
| June 2013 | - | $1.87 M(+37.0%) |
| Mar 2013 | - | $1.37 M(-21.0%) |
| Dec 2012 | $1.73 M(+45.7%) | $1.73 M(-16.1%) |
| Sept 2012 | - | $2.06 M(+18.3%) |
| June 2012 | - | $1.74 M(-3.4%) |
| Mar 2012 | - | $1.80 M(+51.9%) |
| Dec 2011 | $1.19 M(+12.4%) | $1.19 M(-48.3%) |
| Sept 2011 | - | $2.30 M(-32.8%) |
| June 2011 | - | $3.42 M(+40.2%) |
| Mar 2011 | - | $2.44 M(+130.8%) |
| Dec 2010 | $1.06 M(-33.8%) | $1.06 M(+39.2%) |
| Sept 2010 | - | $758.20 K(+27.3%) |
| June 2010 | - | $595.50 K(-55.8%) |
| Mar 2010 | - | $1.35 M(-15.6%) |
| Dec 2009 | $1.60 M(-42.0%) | $1.60 M(+70.2%) |
| Sept 2009 | - | $937.30 K(-34.2%) |
| June 2009 | - | $1.42 M(-33.9%) |
| Mar 2009 | - | $2.15 M(-21.6%) |
| Dec 2008 | $2.75 M(+1199.2%) | $2.75 M(-18.5%) |
| Sept 2008 | - | $3.38 M(-6.1%) |
| June 2008 | - | $3.59 M(+7578.8%) |
| Mar 2008 | - | $46.80 K(-77.9%) |
| Dec 2007 | $211.60 K(-92.6%) | $211.60 K(-72.7%) |
| Sept 2007 | - | $774.70 K(-47.2%) |
| June 2007 | - | $1.47 M(-33.1%) |
| Mar 2007 | - | $2.19 M(-23.8%) |
| Dec 2006 | $2.87 M | $2.87 M(-19.7%) |
| Sept 2006 | - | $3.58 M(-26.4%) |
| June 2006 | - | $4.86 M(>+9900.0%) |
| Feb 2006 | - | $2200.00(-47.6%) |
| Nov 2005 | - | $4200.00(-4.5%) |
| Aug 2005 | - | $4400.00 |
FAQ
- What is Cytosorbents annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Cytosorbents?
- What is Cytosorbents annual cash & cash equivalents year-on-year change?
- What is Cytosorbents quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Cytosorbents?
- What is Cytosorbents quarterly cash and cash equivalents year-on-year change?
What is Cytosorbents annual cash & cash equivalents?
The current annual cash & cash equivalents of CTSO is $14.13 M
What is the all time high annual cash & cash equivalents for Cytosorbents?
Cytosorbents all-time high annual cash & cash equivalents is $71.42 M
What is Cytosorbents annual cash & cash equivalents year-on-year change?
Over the past year, CTSO annual cash & cash equivalents has changed by -$8.01 M (-36.19%)
What is Cytosorbents quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of CTSO is $5.69 M
What is the all time high quarterly cash and cash equivalents for Cytosorbents?
Cytosorbents all-time high quarterly cash and cash equivalents is $87.98 M
What is Cytosorbents quarterly cash and cash equivalents year-on-year change?
Over the past year, CTSO quarterly cash and cash equivalents has changed by -$2.67 M (-31.99%)